cancer patients irrespective of drug is identified. The estimate combines the prediction of number of newly diagnosed and treated patients with the prediction of number of patients who were diagnosed previously and would probably be treated in a given year due to a relapse or progression of the primary malignant disease. In the second step patients are localised to individual drugs according to treatment scheme provided by the panel of experts, adjusted using information from clinical registries. RESULTS:
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RTI Health Solutions, Barcelona, Spain, 2 RTI Health Solutions, Research Triangle Park, NC, USA, 3 RTI-Health Solutions, Otawa, Ontario, Canada OBJECTIVES: Despite implementation of radical cost control measures, pharmaceutical expenditure is expected to keep increasing due to highly innovative, expensive drugs, including immunotherapeutics. The objective of this study was to understand how different markets are responding to cost containment pressures, using a compareand-contrast approach of reimbursement decisions for three recently approved treatments for metastatic renal cell carcinoma (mRCC) . Based on the findings we propose fundamentals to build acceptable reimbursement strategies for AI, including cancer vaccines. METHODS: We examined commonalities and differences of three drugs for mRCC, assessing drug costs, health technology assessments (HTA), and reimbursement decisions across 7 countries with similar pharmaceutical funding schemes (Canada, France, Germany, Italy, Spain, Sweden, and the UK). In each of the 7 countries primary reimbursement criteria for these drugs were identified, local HTAs were reviewed, and specific qualitative research with local payers and experts was conducted. For country comparisons, drug treatment costs were calculated from a payer perspective (6 weeks therapy). RESULTS: Treatment cost differences in the seven countries were minimal and mostly related to exchange rates indicating that, for innovative drugs, price convergence has been achieved in these countries. More than 70% of the total HTA evaluations conducted involved immunotherapeutics. Only the SMC assessment recommended against the use of the 3 studied drugs. Most countries apply or are studying some type of risk sharing scheme or access/restriction program for forthcoming drugs. CONCLUSIONS: Most payers accept high priced drugs; however, they certainly restrict patient access or set up different types of agreements with suppliers to be able to maintain budget control. Current reimbursement schemes in the countries studied will need to evolve according to similar parameters in order to give access to highly complex therapies as AI. In each country, the feasibility of implementing processes to track drug use, cost and outcomes will determine how these reimbursement schemes develop.
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RURAL-URBAN DIFFERENCES IN COLORECTAL CANCER HOSPITALIZATIONS IN WEST VIRGINIA, USA
Shah N West Virginia University, Morgantown, WV, USA OBJECTIVES: Colorectal cancer (CRC) is the third leading cause of cancer mortality in the US with disparities in risk between rural and urban patients. The aim of the study was to: 1) describe the characteristics of hospital admissions, 2) compare the length of stay and in-hospital deaths in rural and urban West Virginia residents with a primary diagnosis of CRC. METHODS: Data from the Health Care Cost and Utilization Project, State Inpatient Database for the years 2003, 2005, 2006 and 2007 were used to perform analyses of all discharges with a primary diagnosis of CRC. Chi square tests compared categorical descriptive statistics between rural and urban cases. One-way ANOVA compared mean length of stay based on rural-urban category. RESULTS: Admissions for CRC as a primary diagnosis decreased constantly from 882 in 2003 to 787 in 2007. In-hospital deaths rose steadily from 5.1% in 2003 to 7% in 2006, but fell to 5.7% in 2007. Mean ages ranged between 69.6 years and 70.3 years and percentage of female admissions ranged between 53.1% and 55.2% over the four years. A greater proportion of patients from large metros (17.4%) died in-hospital compared to small metros (7.0%), micropolitan (4.4%) and rural (5.2%) areas (p 0.001). Leading primary payer was Medicare for all four locations. Rural patients had the shortest mean length of stay (9.0 days). The mean length of stay differed significantly between rural (9.0 days) and micropolitan (10.0 days) patients. CONCLUSIONS: Colorectal cancer provides a significant burden to the health care system in West Virginia. Unlike previously reported in certain other states and countries, a greater proportion of urban residents in West Virginia are dying in-hospital due to CRC. The reasons for these disparities go beyond demographic differences between rural-urban residents and need to be explored.
PCN164 TWO DIFFERENT DOSES OF PALONOSETRON (PAL) FOR PREVENTION OF CHEMOTHERAPY-INDUCED VOMITING (CIV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT: SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)
Engel T 1 , Clark O 1 , Paladini L 1 , Faleiros E 1 , Clark LG 2 , Pegoretti B 1 1 Evidencias Medicas, Campinas, SP, Brazil, 2 Evidencias Medicas, Campinas, sp, Brazil OBJECTIVES: Chemotherapy-induced vomiting (CIV) is a frequent side effect of cancer treatment, with debilitating symptoms and negative effects on quality of life. CIV may be acute (within 24 hours of chemotherapy) or delayed (up to 7 days later). Different doses of PAL are available but the ideal one is still unknown. A recent metaanalysis demonstrated that PAL is more effective than other serotonin inhibitors in preventing nausea and CIV in patients receiving MoHE chemotherapy. We aimed to perform a SR and MA of all randomized controlled trials (RCT) comparing PAL 0.25 mg (or 0.3-1 mcg/kg) to PAL 0.75 mg (or 10 mcg/kg) as single intravenous doses in this setting of patients. METHODS: We searched several databases: MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoints were the incidence of acute and delayed vomiting. The side effects of each treatment were analyzed. A subgroup analysis was planned and performed to evaluate the influence of the use of corticosteroids. The results of individual studies were pooled in MA, using the RevMan 5.1 software. The results are expressed as Risk Ratio (RR) and the correspondent 95% Confidence Interval (CI). RESULTS: Eight studies with 1674 patients were included. There was no difference between the efficacy of the evaluated doses in preventing either acute (RR 1.04; CI 95% 0.91 to 1.18; p 0.60) or delayed vomiting (RR 1.01; CI95% 0.90 to 1.13; p 0.89). There were no differences in side effects either: headache (RR 0.88; CI95% 0.64 to 1.20; p 0.41), dizziness (RR 1.20; CI95% 0.33 to 4.35; p 0.78), constipation (RR 0.67; CI95% 0.42 to 1.06; p 0.09) or diarrhea (RR 1.51; CI95% 0.43 to 5.31; p 0.52). The subgroup analysis found that the addition of corticosteroids had no impact on the efficacy of PAL. CONCLUSIONS: Both doses of PAL have equal efficacy and safety profile in preventing CIV in patients receiving MoHE chemotherapy. The choice of scheme, in this situation, must be the least costly one.
PCN165 SYSTEMATIC REVIEW OF PUBLISHED META-ANALYSES, SYSTEMATIC REVIEWS, AND HEALTH TECHNOLOGY ASSESSMENTS OF RITUXIMAB FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA
Santos EA, Minowa E Roche Brazil, Sao Paulo, SP, Brazil OBJECTIVES: To perform a review of the published meta-analyses, systematic reviews and health technology assessments reports (HTAR) which evaluated the use of rituximab for the treatment of non-Hodgkin lymphoma (NHL) regarding its benefits, safety profile and cost-effectiveness. METHODS: A search of MEDLINE, Lilacs, Cochrane library, Web of science and INAHTA websites from 1990 to 2009 was conducted. The following MESH terms were used: "Meta-Analysis", "Systematic Reviews", "Lymphoma, Non-Hodgkin", "Lymphoma, Large B-Cell, Diffuse" and "rituximab". Included studies were those which evaluated the use of rituximab alone and/or in combination with other therapies in first line, second line and maintenance therapy for naive, refractory patients or relapsed disease in different patient characteristics.
